CD274 and renal cell carcinoma: Thus, this SLR generated a large, unique evidence base encompassing real-world evidence on the treatment of advanced/metastatic melanoma, NSCLC, and RCC that enriches our understanding of the degree of value and improvements in outcomes that anti-PD-(L)1 therapy has brought to cancer patients in actual clinical practice.